BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 18270864)

  • 21. B-cell depletion in the treatment of mixed cryoglobulinemia.
    Sansonno D; Tucci FA; Montrone M; Troiani L; Sansonno L; Gatti P; Lauletta G
    Dig Liver Dis; 2007 Sep; 39 Suppl 1():S116-21. PubMed ID: 17936212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The challenge of treating hepatitis C virus-associated cryoglobulinemic vasculitis in the era of anti-CD20 monoclonal antibodies and direct antiviral agents.
    Roccatello D; Sciascia S; Rossi D; Solfietti L; Fenoglio R; Menegatti E; Baldovino S
    Oncotarget; 2017 Jun; 8(25):41764-41777. PubMed ID: 28454112
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Health-related quality of life in severe cryoglobulinaemic vasculitis and improvement after B-cell depleting therapy.
    Quartuccio L; Isola M; Masolini P; Scaini P; Zani R; Tavoni A; Pietrogrande M; Bombardieri S; De Vita S
    Clin Exp Rheumatol; 2013; 31(1 Suppl 75):S9-14. PubMed ID: 23044040
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis.
    Sène D; Ghillani-Dalbin P; Amoura Z; Musset L; Cacoub P
    Arthritis Rheum; 2009 Dec; 60(12):3848-55. PubMed ID: 19950292
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease.
    Petrarca A; Rigacci L; Caini P; Colagrande S; Romagnoli P; Vizzutti F; Arena U; Giannini C; Monti M; Montalto P; Matucci-Cerinic M; Bosi A; Laffi G; Zignego AL
    Blood; 2010 Jul; 116(3):335-42. PubMed ID: 20308604
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cryoglobulinaemia type III with severe neuropathy and immune complex glomerulonephritis: remission after plasmapheresis and rituximab.
    Braun A; Neumann T; Oelzner P; Hein G; Gröne HJ; Ziemer M; Wolf G
    Rheumatol Int; 2008 Mar; 28(5):503-6. PubMed ID: 17924113
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How HCV has changed the approach to mixed cryoglobulinemia.
    Della Rossa A; Baldini C; Tavoni A; Bombardieri S
    Clin Exp Rheumatol; 2009; 27(1 Suppl 52):S115-23. PubMed ID: 19646357
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry.
    Terrier B; Launay D; Kaplanski G; Hot A; Larroche C; Cathébras P; Combe B; de Jaureguiberry JP; Meyer O; Schaeverbeke T; Somogyi A; Tricot L; Zénone T; Ravaud P; Gottenberg JE; Mariette X; Cacoub P
    Arthritis Care Res (Hoboken); 2010 Dec; 62(12):1787-95. PubMed ID: 20740617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia.
    Saadoun D; Resche Rigon M; Sene D; Terrier B; Karras A; Perard L; Schoindre Y; Coppéré B; Blanc F; Musset L; Piette JC; Rosenzwajg M; Cacoub P
    Blood; 2010 Jul; 116(3):326-34; quiz 504-5. PubMed ID: 20439619
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rituximab in cryoglobulinaemic vasculitis, evidence for its effectivity: a case report and review of literature.
    Wink F; Houtman PM; Jansen TL
    Clin Rheumatol; 2011 Feb; 30(2):293-300. PubMed ID: 21053035
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab plus belimumab in non-infectious refractory cryoglobulinemia vasculitis: A pilot study.
    Saadoun D; Ghembaza A; Riviere S; Mekinian A; Boutemy J; Leroux G; Domont F; Maillard H; Vautier M; Cacoub P
    J Autoimmun; 2021 Jan; 116():102577. PubMed ID: 33248866
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis.
    Lamprecht P; Lerin-Lozano C; Merz H; Dennin RH; Gause A; Voswinkel J; Peters SO; Gutzeit O; Arlt AC; Solbach W; Gross WL
    Ann Rheum Dis; 2003 Dec; 62(12):1230-3. PubMed ID: 14644867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study.
    Dammacco F; Tucci FA; Lauletta G; Gatti P; De Re V; Conteduca V; Sansonno S; Russi S; Mariggiò MA; Chironna M; Sansonno D
    Blood; 2010 Jul; 116(3):343-53. PubMed ID: 20308602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy.
    Roccatello D; Sciascia S; Rossi D; Alpa M; Naretto C; Baldovino S; Menegatti E; La Grotta R; Modena V
    Nephrol Dial Transplant; 2011 Dec; 26(12):3987-92. PubMed ID: 21385860
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Hepatitis C virus-related cryoglobulinemic vasculitis with renal involvement: current possibilities of treatment].
    Gordovskaia NB; Kozlovskaia LV; Milovanova SIu; Ignatova TM; Korotchaeva IuV
    Ter Arkh; 2013; 85(6):78-84. PubMed ID: 23866603
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment for cryoglobulinemic and non-cryoglobulinemic peripheral neuropathy associated with hepatitis C virus infection.
    Benstead TJ; Chalk CH; Parks NE
    Cochrane Database Syst Rev; 2014 Dec; (12):CD010404. PubMed ID: 25525951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of hepatitis C-virus-related glomerulonephritis.
    Kamar N; Rostaing L; Alric L
    Kidney Int; 2006 Feb; 69(3):436-9. PubMed ID: 16514428
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of monoclonal antibody (rituximab) in the treatment of type II mixed cryoglobulinemia.
    Rego TC; Massumoto CM; Batista RS; Moura LH; Soares LM; Gomes AP
    Braz J Infect Dis; 2007 Feb; 11(1):174-5. PubMed ID: 17625752
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Monoclonal antibodies to B-lymphocytes (rituximab) in the treatment of HCV-associated severe cryoglobulinemic glomerulonephritis].
    Milovanova SIu; Lopatkina TN; Kozlovskaia LV; Krasnova TN
    Ter Arkh; 2007; 79(6):69-72. PubMed ID: 17684972
    [No Abstract]   [Full Text] [Related]  

  • 40. Acute wrist and foot drop associated with hepatitis C virus related mixed cryoglobulinemia: rapid response to treatment with rituximab.
    Uppal R; Charles E; Lake-Bakaar G
    J Clin Virol; 2010 Jan; 47(1):69-71. PubMed ID: 19892591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.